Supplemental Online Content

Sanfilippo R, Hayward RL, Musoro J, et al. Activity of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma: a phase 2 study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). *JAMA Oncol*. Published online August 18, 2022. doi:10.1001/jamaoncol.2022.3218

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure A.



eFigure A: Patient disposition for the Phase II trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma.

eFigure 1



eFigure 2



SUPPLEMENTARY MATERIAL

eTable 1. Summary of main clinical efficacy endpoints.

	Per protocol population (n=38) n(%)	Final decision rule population (n=37) n(%)	Interim decision rule population (n=17) n(%)
Progression free survvival at 12 weeks (binary)			
Progression free at 12 weeks (binary)			
Success (%) [conditional 1-sided 95 % CI]	21 (55.3) [0.408 - 1]	21 (56.8)	11 (64.7)
Response at 12 weeks			
Stable	21 (55.3)	21 (56.8)	11 (64.7)
Progression	12 (31.6)	11 (29.7)	3 (17.6)
Early death	1 (2.6)	1 (2.7)	1 (5.9)
Not evaluable	4 (10.5)	4 (10.8)	2 (11.8)
Objective tumor response rate			
Best overall response			
Complete response	1 (2.6)		
Partial response	2 (5.3)		
Stable disease	22 (57.9)		
Progressive disease	11 (28.9)		
Early death	1 (2.6)		
Not evaluable	1 (2.6)		
Objective response (CR+PR)			
CR+PR (%) [Exact binomial 95 % CI]	(7.9) [1.7% to 21.4%]		
Median time to onset of response	8 mo (range: 5.1 - 8.3 mo)		
Median survival estimate			
Progression free survival (95% CI)	6.5 mo (2.8-10.3 mo)		
Time to progression (95% CI)	7.4 mo (2.8-12.1 mo)		
Overall survival (95% CI)	21.1 mo (14.8-33.5 mo)		

Abbreviations: ; CI, confidence interval; CR, complete response; PR, partial response; Mo, months

SUPPLEMENTARY MATERIAL

eTable 2: Cabazitaxel-related clinical AEs (all grades) occurring in ≥ 10% of patients in the safety population.

	Grade 1 N (%)	Grade 2 N (%)	Grade 3 N (%)	Grade 4 N (%)	Grade 5 N (%)	Grade ≥1 N (%)
All AEs	4 (10.0)	3 (7.5)	13 (32.5)	17 (42.5)	1 (2.5)	38 (95.0)
Anemia		8 (20)	4 (10)			12 (30)
Febrile Neutropenia			9 (22.5)	1 (2.5)		10 (25)
Abdominal Pain		5 (12.5)	1 (2.5)			6 (15)
Constipation	3 (7.5)	1 (2.5)				4 (10)
Diarrhea	11 (27.5)	3 (7.5)	3 (7.5)			17 (42.5)
Dyspepsia	4 (10)	2 (5)				6 (15)
Nausea	10 (25)	6 (15)	1 (2.5)			17 (42.5)
Vomiting	3 (7.5)	2 (5)	1 (2.5)			6 (15)
Fatigue	6 (15)	5 (12.5)	5 (12.5)			16 (40)
Fever	4 (10)	1 (2.5)		1 (2.5)		6 (15)
Pain	3 (7.5)		1 (2.5)			4 (10)
Alanine Aminotransferase Increased	3 (7.5)	1 (2.5)				4 (10)
Lymphocyte Count Decreased	1 (2.5)	3 (7.5)				4 (10)
Neutrophil Count Decreased		1 (2.5)	4 (10)	16 (40)		21 (52.5)
Weight Loss	7 (17.5)	4 (10)				11 (27.5)
White Blood Cell Decreased		1 (2.5)		3 (7.5)		4 (10)
Anorexia	8 (20)	4 (10)	1 (2.5)			13 (32.5)
Arthralgia	1 (2.5)	3 (7.5)				4 (10)
Dysgeusia	5 (12.5)		1 (2.5)			6 (15)